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BamH l polymorphism of the human cytochrome P450 gene, CYP2D6, 
which encodes drug metabolizing enzyme, was studied to find out 
whether variant genotypes of this gene are associated with the 
susceptibility or resistance to bacteriological relapse of pulmonary 
tuberculosis after stopping treatment with short-course 
chemotherapy of 6-8 months duration. The study was carried out in 
control subjects (n=158), patients with pulmonary tuberculosis 
(n=154), patients with bacteriological relapse (n=50) and quiescent 
patients (n=50). No difference in the frequency of variant genotypes 
of BarnH l polymorphism of CYP2D6 gene was observed between 
pulmonary TB patients and control subjects. A trend towards an 
increased frequency of 22 genotype (homozygous for infrequent 
allele 2) was observed in bacteriological relapse patients than 
quiescent patients (odds ratio, OR: 2). Similar increase was 
observed in male relapse patients than male quiescent patients (OR: 
2.2). The present study suggests that 22 genotype of BamH l 
polymorphism of CYP2D6 of human cytochrome P450 gene either 
alone or in combination with closely linked genes may be associated 
with bacteriological relapse especially in male patients of pulmonary 
tuberculosis. 
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INTRODUCTION 
Pulmonary tuberculosis is a 
granulomatous lung disease caused by 
Mycobacterium tuberculosis. Treatment 
with short course chemotherapy with 
Rifampicin containing drug regimens has 
proved to be highly effective (1, 2). lnspite 
of successful treatment with these drugs, a 
proportion of patients relapsed, which 
requires retreatment (1 -3). Our earlier 
studies on human leucocyte antigens 
(HLA) in quiescent and bacteriological 
relapse patients of pulmonary tuberculosis 
revealed the association of HLA-A1 , -B17 
antigens, HLA haplotypes A 1  -B17, A1-  
DR7, HLA-TNFœ haplotypes B17-TNFœ- 
238/A, B17-TNFœ -308/2 and B17-TNFß/2 
with bacteriological relapse (4,5). Studies 
on pharmacogenetics revealed several 
genetic polymorphisms that are involved in 
drug-metabolizing enzymes, transporters, 
receptors and other drug targets and 
shown to be linked to inter individual 
differences in the efficacy or toxicity of 
many medicines (6,7). The human 
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Cytochrome P450 (CYP) family members 
are responsible for the metabolism of 
endogenous substrates, dietary 
compounds and environmental toxins. 
Cytochrome P450 is involved in the 
metabolism of commonly used medicines. 
The polymorphic human cytochrome P450 
gene, CYP2D6, encodes the drug 
metabolizing enzyme debrisoquine 
hydroxylase, a metabolizer for 
debrisoquine and more than 30 other 
drugs (8, 9). To understand whether 
polymorphic variants of drug metabolizing 
enzyme genes such as Cytochrome P450 
gene play any role on bacteriological 
relapse of pulmonary tuberculosis, the 
present study was carried out. We studied 
the BamH l polymorphism of CYP2D6 
gene (human cytochrome P450 gene) to 
find out whether its variant genotypes are 
associated with the susceptibility or 
resistance to bacteriological relapse of 
pulmonary TB after completion of 6-8 
months of short course chemotherapy with 
various anti-TB drugs. 
MATERIALS AND METHODS 
The study subjects were (i) normal healthy 
subjects serving as controls (n=158), (ii) 
pulmonary TB patients (n=154) who were 
sputum positive for M. tuberculosis by 
smear and culture; (iii) patients who had a 
relapse indicated by a sputum culture 
positive for M. tuberculosis (n=50); (iv) 
cured, symptom free, quiescent patients 
(n=50). 
The study patients were selected from an 
earlier chemotherapy study conducted by 
our centre. Patients attending 
Tuberculosis Research Centre (TRC), 
Chennai, with respiratory symptoms and 
radiographic abnormalities suggestive of 
pulmonary TB and who had been cured 
were studied. They were sputum positive 
for M. tuberculosis by smear and culture 
initially. Among the PTB patients, 108 
were males and 46 were females, aged 
40.9±1.0 and 36.9±5.4 years respectively. 
All these patients had received supervised 
short course chemotherapy for 6 to 8 
months duration and had been followed up 
for five years after treatment. During 
follow-up, around 10 percent of the treated 
patients had a bacteriological relapse of 
the disease. The relapse patients were 
treated with other drug regimens and 
cured. 
Patients under follow up were classified as 
having bacteriological relapse or being 
quiescent. The main criteria for relapse 
were clinical deterioration, persistent 
radiograph deterioration (chest X-ray) and 
sputum cultures positive for M. 
tuberculosis. The relapse patients were 
culture proven cases. Patients who had a 
bacteriological relapse (n=50) and an 
equal number of patients with quiescent 
disease (n=50), matched for treatment 
regimen and duration of follow up were 
selected. The relapse and quiescent 
patients were age matched. Among the 
relapse patients, 42 were males and 8 
were females aged 41±1.9 years and 
40±4.9 years respectively. Among the 
quiescent patients 36 were males and 14 
were females, aged 40±1.6 years and 
40±2.5  years respectively. The relapse 
patients and the quiescent patients were 
recruited from the same environment. 
They belonged to the same 
socioeconomic status and the same ethnic 
origin. 
The controls comprised of spouses of the 
patients (n=76) (family contacts) who were 
living together with the patients before, 
during and after treatment for a period of 
10-15 years and staff of TRC (n=72) 
working for more than 3 years. Of the 
controls, 79 were males and 79 were 
females aged 40±1.1 and 36.8±1.0 years 
respectively. All the family contacts and 
other control subjects were clinically 
normal at the time of blood collection. The 
patients and the spouses were not 
© Publication of Indian Association of Biomedical Scientists 28 
BamH 1 POLYMORPHISM 
consanguineous. The other control 
subjects were not related to any of the 
patients. The patients and the controls 
were randomly selected and belonged to 
the same ethnic group. 
Genomic DNA was extracted from the 
peripheral blood white cells using a salting 
out procedure (10). For BamH l 
polymorphism, the exon 2 and parts of the 
flanking introns of the CYP2D6 gene was 
amplified using the following primers as 
described earlier (8, 11). Primers for intron 
1 (base pairs 585 to 605): 5'-GAT GAG 
TTA GTC CTG AGT GCC - 3' and for 
intron 2 (base pairs 11 62 to 1 182); 5'-TCC 
CAC GGA AAT CTG TCT CTG - 3'. 
The polymerase chain reaction (PCR) 
conditions were: an initial denaturation 
step at 94°C for 4 mins followed by 35 
cycles of denaturation at 94°C for 30 secs, 
annealing 58°C for 30 secs and extension 
72°C for 60 secs and finally 2 minutes 
extension at 72°C, using 10X PCR 
amplification buffer (Gibco BRL, Grand 
Island, NY, USA),1mM MgS04, 0.6 mM of 
dNTPs, 5pmoles of each primer, (Gibco 
BRL, Grand Island, NY, USA) 100 ng of 
DNA and 1unit of Taql polymerase (Gibco 
BRL, Grand Island, NY, USA) in a 25 µI 
reaction mix in a programmable 
thermocycler (MJ Research, Inc., 
Watertown, MA, USA). 
The amplified 598 base pair product was 
checked on a 1% agarose gel stained with 
ethidium bromide along with F X174 Hae lll 
digest as a marker. 5 µl of the PCR 
product was restriction digested with 3-5 
units of BamH l enzyme at 37°C for 3 
hours and run on 1.5% gel for 45 minutes 
at 80V along with F X174 Hae lll marker. 
Absence of BamH l restriction site (598 bp) 
was assigned as common allele and the 
presence of restriction site resulting in 349 
and 249 bp fragments was assigned as 
infrequent allele 2. Genotypes were 
assigned accordingly: homozygotes for 
common allele 11 and homozygotes for 
infrequent allele 22. Presence of 598, 349 
& 249 bp fragments was assigned as 
heterozygotes 12. 
The frequencies of the genotypes in the 
patient group and controls were analysed 
using x2 test with Yate's correction (x2y) 
using Statcalc program (Epi Info, Version- 
5; USD; Stone Mountain, GA) to find out 
the statistical significance, Odds ratio (OR) 
and Confidence Interval (CI). 
RESULTS 
No difference in the genotype frequency of 
BarnH l polymorphic variants of CYP2D6 
gene was observed between the control 
group and pulmonary tuberculosis group. 
Since, tuberculosis is more prevalent in 
males, the data were analysed further for 
male and female controls and patients. 
Interestingly, a significantly increased 
genotype frequency of 22 (homozygous 
for infrequent allele) of CYP2D6 gene was 
observed in female control subjects than 
male controls (P=0.03; Odds Ratio (OR) 
2.3; 95% Confidence interval = 1.07-5.23) 
whereas, no such increase in the 22 
genotype was observed in female 
pulmonary TB patients than male patients 
(Table 1). 
A trend towards an increased frequency of 
22 genotype (homozygous for infrequent 
allele) was observed in bacteriological 
relapse patients than quiescent patients 
(Odds ratio = 2.0). The data were further 
analysed for male and female relapse and 
quiescent cases. An increased frequency 
of the genotype 22 was observed in male 
relapse patients than male quiescent 
patients (Odds ratio=2.2). However, these 
increases were not significant (Table 2). 
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12 43.7 49.4 49.4 38.0 50.0 47.8 
(69) (76) (39) (30) (54) (22) 
22 27.2 25.3 19* 35.4* 26.8 21.8 
(43) (39) ( 15) (28) (29) (10) 
n = subjects studied: numbers in parentheses represent the subjects positive for variant genotypes: 
PTB : pulmonary tuberculosis; 
*Female vs male X2yP=0.03: Odds ratio = 2.34; 95% confidence interval = 1.07-5.23 
Table 2 Genotype frequency of BamH l polymorphism of CYP2D6 gene among 
quiescent and relapse patients of pulmonary TB 
22 18* 30* 16.7@ 21.4 31.0@ 25 
(9) (15) (6) (3) (13) (2) .......................................................................................................................... 
n = subjects studied; numbers in parentheses represent the subjects positive for variant genotypes 
*P=0.24 (not significant); odds ratio = 1.95: 95% confidence interval = 0.69-5.69 
@P=0.23 (not significant): odds ratio of n = 2.24; 95% confidence interval = 0.67-8.13 
~~ ~ 
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DISCUSSION REFERENCES 
The frequency of variant genotypes (11, 
12, 22) of BamH l polymorphism of 
CYP2D6 gene was similar among controls 
and pulmonary TB patients indicating a 
lack of association between the gene and 
susceptibility to pulmonary TB. 
The frequency of 22 genotype was higher 
among healthy females than healthy 
males suggesting that this genotype in 
combination with closely linked genes 
along with other host factors such as 
hormones may influence drug metabolism 
in males and females. It is known that sex 
steroid hormones are synthesized from a 
series of enzymatic reactions involving 
several of the cytochrome P450 enzymes 
(12). The drug metabolism enzyme gene 
(CYP2D6) is one of the cytochrome P450 
gene family (1 3). The observed difference 
in the male and female subjects may 
probably be due to gene-gene interaction. 
The frequency of genotype 22 was higher 
among relapse patients compared to 
quiescent patients particularly among 
males. It is likely that closely linked 
CYP2D6 genes in combination with other 
genes and host factors may influence the 
metabolism of anti-tuberculous drugs 
during treatment. Due to altered drug 
metabolism, some of the bacteria may 
undergo dormancy and later be 
reactivated after completion of treatment. 
Further research may explore whether 
other alleles of CYP2D6 gene and other 
genes of Cytochrome P450 family are 
associated with bacteriological relapse of 
pulmonary TB. 
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